ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2016
What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Preferences of People Living with HIV for Long-Acting Antiretroviral Treatment in Germany: Evidence from a Discrete Choice Experiment.The patient · 2023Pooled it
- Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review.BMC medical informatics and decision making · 2019Pooled it
- Discrete Choice Experiments in Health Economics: Past, Present and Future.PharmacoEconomics · 2019Pooled it
- A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide.Endocrine · 2020Trial
- The elicitation of quality of life preferences for lung cancer treatment from the perspective of patients and treating physicians: results of two discrete choice experiments.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti-Hyperglycemic Medications Choices for Type 2 Diabetes.Journal of diabetes · 2026Article
- Article
- The elicitation of patient preferences for hip replacement surgery: a discrete choice experiment.BMC health services research · 2025Article
- The elicitation of patient and physician preferences for calculating consumer-based composite measures on hospital report cards: results of two discrete choice experiments.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Preferences for Monitoring Comprehensive Heart Failure Care: A Latent Class Analysis.The patient · 2024Article
- Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.Journal of managed care & specialty pharmacy · 2023Review
- Identifying patient preferences for diabetes care: A protocol for implementing a discrete choice experiment in Samoa.PloS one · 2023Article
- Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Investigating patients' preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China.BMC public health · 2022Article
- Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment.Journal of diabetes and metabolic disorders · 2022Article
- Preferences for Patients with Type 2 Diabetes Mellitus for Medications in Shandong Province, China: A Discrete Choice Experiment.Patient preference and adherence · 2022Article
- Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Article
- Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment.Frontiers in public health · 2021Article
- Preferences of people with type 2 diabetes for telemedical lifestyle programmes in Germany: protocol of a discrete choice experiment.BMJ open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this empirical study is to evaluate patient preferences for different characteristics of oral type 2 diabetes mellitus (T2DM) treatment. As T2DM treatment requires strict adherence, patient needs and preferences should be taken into consideration.
methodsBased on a qualitative and quantitative analysis, a discrete choice experiment (DCE) was applied to identify patient preferences. Apart from six identical attributes (adjustment of glycated hemoglobin [HbA1c], prevention of hypoglycemia, risk of genital infection, risk of gastrointestinal problems, risk of urinary tract infection, and weight change), one continuous variable of either "additional healthy life years" (AHY) or "additional costs" attribute (AC) was included. The DCE was conducted using a fractional factorial design, and the statistical data analysis used random effect logit models.
resultsIn total, N = 626 (N = 318 AHY + N = 308 AC) T2DM patients participated in the survey. The estimation revealed a clear dominance for prevention of hypoglycemia (coefficient 0.937) and adjustment of HbA1c (coefficient 0.541). The attributes, "additional healthy life years" (coefficient 0.458) or "additional costs" (coefficient 0.420), were in the middle rank and both of significant impact. The side effects, risk of genital infection (coefficient 0.301), risk of gastrointestinal problems (coefficient 0.296), and risk of urinary tract infection (coefficient 0.241) followed in this respective order. Possible weight change (coefficient 0.047) was of less importance (last rank) to the patients in this evaluation.
conclusionsThese survey results demonstrate how much a (hypothetical) T2DM oral treatment characteristic affects the treatment decision. The preference data can be used for risk-benefit assessment, cost-benefit assessment, and the establishment of patient-oriented evidence. Understanding how patients perceive and value different aspects of diabetes oral treatment is vital to the optimal design and evaluation of treatment options. The present results can be an additional source of information for design, assessment, and decision in T2DM treatment regimes. As such, more effective and efficient care of patients can be achieved, thereby increasing adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.